- Home
- MGNX vs DC Comparison
MGNX vs DC Comparison
Compare MGNX & DC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- DC
- Stock Information
- Founded
- MGNX 2000
- DC 2017
- Country
- MGNX United States
- DC United States
- Employees
- MGNX N/A
- DC N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- DC Precious Metals
- Sector
- MGNX Health Care
- DC Basic Materials
- Exchange
- MGNX Nasdaq
- DC Nasdaq
- Market Cap
- MGNX 257.3M
- DC 212.5M
- IPO Year
- MGNX 2013
- DC N/A
- Fundamental
- Price
- MGNX $3.23
- DC $2.16
- Analyst Decision
- MGNX Hold
- DC Buy
- Analyst Count
- MGNX 10
- DC 1
- Target Price
- MGNX $7.17
- DC $6.00
- AVG Volume (30 Days)
- MGNX 465.7K
- DC 382.2K
- Earning Date
- MGNX 11-05-2024
- DC 11-13-2024
- Dividend Yield
- MGNX N/A
- DC N/A
- EPS Growth
- MGNX N/A
- DC N/A
- EPS
- MGNX N/A
- DC N/A
- Revenue
- MGNX $141,329,000.00
- DC N/A
- Revenue This Year
- MGNX $174.73
- DC N/A
- Revenue Next Year
- MGNX N/A
- DC N/A
- P/E Ratio
- MGNX N/A
- DC N/A
- Revenue Growth
- MGNX 16.68
- DC N/A
- 52 Week Low
- MGNX $2.95
- DC $1.84
- 52 Week High
- MGNX $21.88
- DC $3.25
- Technical
- Relative Strength Index (RSI)
- MGNX 42.79
- DC 45.80
- Support Level
- MGNX $3.10
- DC $2.05
- Resistance Level
- MGNX $3.30
- DC $2.19
- Average True Range (ATR)
- MGNX 0.19
- DC 0.07
- MACD
- MGNX 0.00
- DC -0.00
- Stochastic Oscillator
- MGNX 25.45
- DC 36.67
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About DC Dakota Gold Corp.
Dakota Gold Corp is a gold exploration and development company with a specific focus on revitalizing the Homestake District in Lead, South Dakota. Dakota Gold has high-caliber gold mineral properties covering over 48 thousand acres surrounding the historic Homestake Mine.